In patients with HCC, the combination of anti-PD-1 therapy and LDHA inhibitors has demonstrated stronger anti-tumor effects than monotherapy with anti-PD-1 antibodies (Gu et al., 2022b). The gene discussed is LDHA; the disease is neoplasm.